Josefa Maria Sanchez-Reyes

Josefa Maria Sanchez-Reyes

Auto-generated profile, based on publicly available information

Josefa Maria Sanchez-Reyes

Department of Paediatrics, Obstetrics and Gynecology, University of Valencia

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2024 in Fertility and Sterility
Verified
Journal Article
Closed access
PDPatricia Diaz-Gimeno
Patricia Diaz-Gimeno
PSPatricia Sebastián-León
Patricia Sebastián-León
KSKatharina Spath
Katharina Spath
DMDiana Marti-Garcia
Diana Marti-Garcia
JSJosefa Maria Sanchez-Reyes
Josefa Maria Sanchez-Reyes
APAntonio Pellicer
Antonio Pellicer

6 November 2025 in medRxiv
Verified
Preprint
Open access
PDF file
APAntonio Parraga-Leo
Antonio Parraga-Leo
PSPatricia Sebastián-León
Patricia Sebastián-León
JSJosefa María Sanchez-Reyes
Josefa María Sanchez-Reyes
FSFrancisco Jose Sanz
Francisco Jose Sanz
MVMaria Del Carmen Vidal
Maria Del Carmen Vidal
PDPatricia Diaz-Gimeno
Patricia Diaz-Gimeno
STUDY QUESTION: Which mechanisms of action and candidate drugs can be used to treat endometrial failure caused by molecular alterations rather than endometrial timing? SUMMARY ANSWER: Genistein, pioglitazone, alprostadil, flunisolide, and tenoxicam emerged as potential therapies to treat two molecular causes of endometrial failure not originating in endometrial timing. WHAT IS KNOWN ALREADY: Several studies have described molecular profiles of endometrial failure unrelated to endometrial timing and proposed diagnostic tools based on clinical and transcriptomic data, but effective therapeutic options remain lacking. Hence, there is a pressing need for tailored treatments to enable personalised medicine in endometrial-factor infertility. STUDY DESIGN, SIZE, DURATION: This multicentre prospective study, conducted at 5 fertility clinics in Spain between January 2019 and August 2022, included 192 patients undergoing in vitro fertilisation with hormone replacement therapy, whose endometrial biopsies were collected during the mid-secretory phase. PARTICIPANTS/MATERIALS, SETTING, METHODS: Of 291 endometrial biopsies, 192 met the quality criteria and 161 were classified according to clinical and transcriptomic data using a semi-supervised learning model for prognosis. Before classification, transcriptomic variation related to endometrial timing was corrected using our validated transcriptomic endometrial-dating model. Profiles were analysed using systems pharmacology approaches combining network analysis and reversal signature matching to identify therapeutic drugs capable of reversing molecular disruption. Candidate drugs were grouped by mechanism of action and prioritised by side-effect profile. Selected drugs were validated in endometrial cells through RT-PCR, F-actin staining, and enzyme-linked immunosorbent assays. MAIN RESULTS AND THE ROLE OF CHANCE: Four transcriptomic profiles were identified using artificial intelligence models, each with distinct clinical implications. Two profiles were associated with poor prognosis: clinical miscarriage-associated (CMA, n = 27) and biochemical miscarriage-associated (BMA, n = 16). CMA was characterised by upregulation of differentiation-related genes and BMA by upregulation of immune-related genes. The 4 profiles were homogeneous in demographic and embryological parameters (age, BMI, and embryo quality), reinforcing their biological relevance. Approved drugs capable of reversing these disrupted expression patterns were identified. Both BMA and CMA were linked to abnormal decidualisation, while BMA also showed immune dysregulation. Genistein and pioglitazone promoted decidualisation in vitro, whereas alprostadil, flunisolide, and tenoxicam inhibited immune responses in endometrial cell cultures, supporting their potential therapeutic role in endometrial failure not originating in endometrial timing. LIMITATIONS, REASONS FOR CAUTION: Although our artificial intelligence-based stratification model revealed clinical and functional differences among profiles, it was designed for drug repurposing rather than predictive diagnosis. A larger, specifically designed study would be required to validate predictive performance and generalisability. Further clinical trials are needed to evaluate the proposed drugs as personalised treatments for this condition. WIDER IMPLICATIONS OF THE FINDINGS: This is the first application of a systems-based drug repurposing strategy in IVF to develop tailored therapeutic interventions. We propose genistein, pioglitazone, alprostadil, flunisolide, and tenoxicam as approved, safe drugs identified through an evidence-based approach that could prevent loss of good-quality embryos and miscarriage due to maternal endometrial factors. These findings, supported by functional in vitro validation, pave the way for future clinical trials advancing personalised medicine in endometrial-factor infertility. TRIAL REGISTRATION NUMBER: Not applicable

8 November 2024 in medRxiv
Verified
Preprint
Open access
PDF file
JSJosefa Maria Sanchez-Reyes
Josefa Maria Sanchez-Reyes
APAntonio Parraga-Leo
Antonio Parraga-Leo
PSPatricia Sebastián-León
Patricia Sebastián-León
CVCarmen Vidal
Carmen Vidal
DMDiana Marti-Garcia
Diana Marti-Garcia
PDPatricia Diaz-Gimeno
Patricia Diaz-Gimeno
Background: Independent of endometrial timing, there are molecular causes of implantation failure that disrupt the endometrial transcriptome in the mid-secretory phase. However, the molecular mechanisms disrupting the window of implantation (WOI) remain poorly understood. The molecular heterogeneity of this endometrial disruption must be characterized to develop personalized and more accurate diagnostic tools for preventive medicine, particularly for patients with a high risk of endometrial failure. Objective(s): This study aimed to stratify and characterize the disrupted WOI patterns using endometrial timing-corrected whole gene expression and artificial intelligence (AI) models in in vitro fertilization (IVF) patients undergoing hormone replacement therapy (HRT). Study design: This multicenter prospective study was conducted between January 2019 and August 2022. Endometrial biopsies were collected during the mid-secretory phase for whole endometrial transcriptome analysis using RNA-Sequencing. To identify disruptions in the WOI, the transcriptomic variation due to cyclic endometrial tissue changes was removed. Out of 195 biopsies sequenced, 131 were derived from patients that met the clinical criteria to be classified as having a poor prognosis (≥3 implantation failures, n=32) or good prognosis (<3 implantation failures, n=99). The 131 patients were randomly allocated to training (n=105) and test (n=26) sets for biomarker signature discovery and assessment of predictive performance, respectively. The reproductive outcomes of the single embryo transfer immediately after biopsy collection were analyzed. Differential gene expression and functional analyses were performed to characterize molecular profiles. Finally, a quantitative polymerase chain reaction (qPCR) assay was used to corroborate the differential expression of six potential biomarkers. Results: With the dichotomous clinical classification of poor or good reproductive prognosis, there was no transcriptomic distinction between patients with a history of implantation failures during HRT endometrial preparation. Alternatively, using an AI model to stratify IVF patients based on the probability of endometrial disruption revealed molecular and clinical differences between profiles. Patients were stratified into four reproductive prognosis-related profiles, p1 (n=24), p2 (n=14), c2 (n=32) and c1 (n=61). The highest pregnancy rate (PR) was associated with c1 (91%) and the highest ongoing pregnancy rate (OPR) was associated with c2 (78%), linking these profiles to good reproductive prognoses. On the other hand, p1 had the highest biochemical miscarriage rate (BMR; 43%) while p2 had the highest clinical miscarriage rate (CMR; 43%). Notably, both p1 and p2 were related to lower PR and OPR, supporting that these profiles were associated with poor prognoses. Regarding the functional characterization in the poor prognosis profiles that were linked to miscarriages, p1 was associated with an excessive immune response against the embryo during early pregnancy stages, while p2 was initially immune-tolerant but rejected the fetus in later stages due to the lack of metabolic response. Conclusion(s): This new AI-based prognostic stratification of IVF patients is promising for the clinical management of endometrial-factor infertility in precision medicine.

12 August 2025 in Human Reproduction
Verified
Journal Article
Open access
JSJosefa Maria Sanchez-Reyes
Josefa Maria Sanchez-Reyes
APAntonio Parraga-Leo
Antonio Parraga-Leo
PSPatricia Sebastián-León
Patricia Sebastián-León
MVMaria del Carmen Vidal
Maria del Carmen Vidal
DMDiana Marti-Garcia
Diana Marti-Garcia
PDPatricia Diaz-Gimeno
Patricia Diaz-Gimeno
STUDY QUESTION: Can the disrupted window of implantation (WOI) be stratified according to transcriptomic patterns associated with reproductive success in IVF patients undergoing HRT? SUMMARY ANSWER: There are four transcriptomic patterns independent of endometrial timing associated with a gradient of reproductive prognosis underlying different molecular pathomechanisms. WHAT IS KNOWN ALREADY: A molecular heterogeneous profile independent of endometrial timing has been discovered as a cause of implantation failure that disrupt the endometrial transcriptome in the mid-secretory phase. However, the molecular heterogeneous patterns underlying the disruption remain poorly identify and understood. Characterizing the molecular heterogeneity of this endometrial disruption is crucial to develop personalized and more accurate diagnostic tools for preventive medicine, particularly for patients with a high risk of endometrial failure. STUDY DESIGN, SIZE, DURATION: In this multicenter prospective study, 195 IVF patients undergoing HRT with endometrial biopsy collection, during mid-secretory phase for endometrial progression evaluation, were recruited between January 2019 and August 2022. Out of 195 patients, 131 were finally included in the following analysis. PARTICIPANTS/MATERIALS, SETTING, METHODS: Endometrial biopsies were processed for whole endometrial transcriptome analysis using RNA-Sequencing. To identify disruptions in the WOI, the transcriptomic variation due to cyclic endometrial tissue changes was removed. Out of 195 biopsies sequenced, 131 were derived from patients that met the clinical criteria to be classified as implantation failure group (≥3 implantation failures, n = 32) or control group (<3 implantation failures, n = 99). An artificial intelligence (AI) model, based on two supervised learning algorithms: support vector machine (SVM) and k-nearest neighbors (kNN), was performed with 131 patients that were randomly allocated to training (n = 105) and test (n = 26) sets for biomarker signature discovery and assessment of predictive performance, respectively. The reproductive outcomes of the single embryo transfer immediately after biopsy collection were analyzed. Differential expression and functional analyses were performed to characterize molecular profiles. Finally, a quantitative PCR (qPCR) assay was used to corroborate the differential expression of six potential biomarkers. MAIN RESULTS AND THE ROLE OF CHANCE: With the dichotomous clinical classification of poor or good reproductive prognosis, there was no transcriptomic distinction between patients with a history of implantation failures during HRT endometrial preparation. Alternatively, using an AI model to stratify IVF patients based on the probability of endometrial disruption revealed molecular and clinical differences between patterns. Patients were stratified into four reproductive prognosis-related profiles: p1 (n = 24), p2 (n = 14), c2 (n = 32) and c1 (n = 61). The highest pregnancy rate (PR) was associated with c1 (91%) and the highest ongoing pregnancy rate (OPR) was associated with c2 (78%), linking these profiles to good reproductive prognoses. On the other hand, p1 had the highest biochemical miscarriage rate (43%) while p2 had the highest clinical miscarriage rate (43%). Notably, both p1 and p2 were related to lower PR and OPR, supporting that these profiles were associated with poor prognoses. Regarding the functional characterization in the poor prognosis profiles that were linked to miscarriages, p1 was associated with an excessive immune response against the embryo during early pregnancy stages, while p2 was initially immune-tolerant but rejected the fetus in later stages due to the lack of metabolic response. LIMITATIONS, REASONS FOR CAUTION: Due to the heterogeneous character of the disrupted WOI and the limited sample size of the different stratified groups, the AI model has limited population inference. However, our significant promising findings provide strong leads for further clinical studies with larger sample sizes. WIDER IMPLICATIONS OF THE FINDINGS: This new transcriptomic taxonomy associated with distinct reproductive outcomes provides clues to design new and more accurate evaluation tools for endometrial-factor infertility. Furthermore, it enables tailoring therapeutic strategies to apply a personalized medicine to each patient suffering from endometrial-factor infertility, improving their odds of getting pregnant. STUDY FUNDING/COMPETING INTEREST(S): This study was supported by the IVI Foundation (1706-FIVI-048-PD); Instituto de Salud Carlos III (ISCIII) and co-funded by the European Regional Development Fund “A way to make Europe” (PI19/00537 [P.D.-G.]) as well as Instituto Carlos III (ISCIII) through project (PI23/00806 [P.D.-G.]) and co-funded by European Union. Patricia Diaz-Gimeno is supported by Instituto de Salud Carlos III (ISCIII) through the Miguel Servet program (CP20/00118) co-funded by the European Union. Patricia Sebastian-Leon and Francisco Jose Sanz are funded by Instituto de Salud Carlos III (ISCIII) through the Sara Borrell postdoctoral program (CD21/00132 [P.S.-L.] and CD23/00032 [F.J.S.]) co-financed by the European Union. Josefa Maria Sanchez-Reyes was supported by a predoctoral fellowship program of the Generalitat Valenciana (ACIF/2018/072 and BEFPI/2020/028). Antonio Parraga-Leo (FPU18/01777) and Diana Marti-Garcia (FPU19/03247) were supported by predoctoral fellowship programs of the Spanish Ministry of Science, Innovation and Universities. The authors declare no conflicts of interest. TRIAL REGISTRATION NUMBER: Not applicable.